Infinity Pharmaceuticals, Inc. (INFI)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.6323 |
| Open | 0.6112 |
| Bid | 0.5901 x 800 |
| Ask | 0.6000 x 4000 |
| Day's range | 0.5613 - 0.6300 |
| 52-week range | 0.4600 - 3.8900 |
| Volume | |
| Avg. volume | 850,862 |
| Market cap | 52.602M |
| Beta (5Y monthly) | 2.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5190 |
| Earnings date | 25 July 2022 - 29 July 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.07 |
- Simply Wall St.
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Business Wire
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 17, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.
- Zacks
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
